Liposomal Amphotericin B Injectable bulk supplier for pharma manufacturers

Liposomal Amphotericin B Injectable 50 mg/vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 50 mg/vial

Reference Brands: AmBisome(US & EU)

Liposomal Amphotericin B binds to fungal ergosterol, creating pores that disrupt cell membrane integrity and cause fungal cell death. It offers broad-spectrum activity, enhanced tissue penetration, and reduced toxicity compared to conventional formulations. Benefits include effective treatment of severe systemic infections with fewer side effects, improving patient outcomes.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Liposomal Amphotericin B is approved in the EU and US for severe fungal infections. In the EU, Gilead’s AmBisome is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and high manufacturing standards. In the US, FDA-approved AmBisome is backed by comprehensive clinical data, biosimilarity assessments, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and submissions, visit PharmaTradz. We facilitate efficient market access for Liposomal Amphotericin B, ensuring adherence to European and American standards for safe, effective antifungal therapy, reducing toxicity while maintaining efficacy in severe infections.

Liposomal Amphotericin B Injectable — third party manufacturing & bulk supply

Liposomal Amphotericin B Injectable 50 mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Liposomal Amphotericin B Injectable is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Liposomal Amphotericin B Injectable listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Liposomal Amphotericin B Injectable →

Back to Listing

Frequently Asked Questions

Liposomal Amphotericin B is used to treat severe systemic fungal infections, including invasive aspergillosis, cryptococcal meningitis, mucormycosis, and systemic candidiasis. The liposomal formulation allows targeted delivery, improved tolerability, and reduced kidney toxicity compared to conventional amphotericin B.

Liposomal Amphotericin B contains amphotericin B encapsulated within liposomes made of phospholipids and cholesterol. This lipid-based structure helps the drug circulate longer in the bloodstream and reduces toxicity while maintaining strong antifungal activity.

The main trade name is AmBisome, widely used in the USA, EU, UK, and global markets.

AmBisome is manufactured by Gilead Sciences. Several other GMP-certified pharmaceutical companies also produce generic liposomal amphotericin B in different regions.

The generic name is amphotericin B (liposomal).

The primary brand name is AmBisome.

Liposomal Amphotericin B is manufactured in Gilead’s regulated facilities in the USA and Europe, along with other approved global GMP manufacturers producing generic versions for international distribution.